Skip to main content
x

Recent articles

Rusfertide still needs to be Verified

An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.

Spurned by Sanofi, Orano turns to Roche

The first fruit of a long-standing deal with Roche enters phase 1 in March.

ASCO-GU – Flare hits an “undruggable” target

But biomarker enrichment and toxicity remain key for FX-909.

FDA red and green lights: February 2026

The month saw the first commissioner's priority voucher approval in oncology.

ASCO-GU 2026 – gauging Welireg’s double win

Welireg looks headed to regulators in second-line and adjuvant kidney cancer.

Kairos expands lung resistance strategy

The company will license EGFR and cMet inhibitors from Celyn.